Final Program ESSM2019

25 21 st CONGRESS OF THE EUROPEAN SOCIETY FOR SEXUAL MEDICINE Saturday, 16 February 2019 l Scientific Program RT-19 ROUND TABLE 08:00–09:00 Linhart Hall Pregnancy, parenthood, sexuality and couples adjustment Chairs: Erika Limoncin, Italy Miso Rajic, Slovenia 001 Intimate, sexual relationship, first-time parents Mijal Luria, Israel 002 Couple difficulties in conception, pregnancy & parenting; psychosexual and couples therapy Jiska Ristori, Italy 003 Sexuality and transition to parenthood Joao Andre Mendes Carvalho, Portugal PS-06 PODIUM SESSION 08:00–09:00 Room M3 Late breaking oral presentations Chairs: Ege Can Serefoglu, Turkey Sam Ward, Belgium 001 The Masturbation Erection Index (MEI): Valida- tion of a new psychometric tool derived from the International Index of Erectile Function (IIEF-6) and from the Erection Hardness Score (EHS) for measuring erectile function during masturbation Erika Limoncin, Italy 002 Preoperative erectile dysfunction is a proxy of chronic kidney disease after surgery for renal cell carcinoma – a pilot study Paolo Capogrosso, Italy 003 Information of erectile dysfunction on youtube: Is it scientific evidence-based? Javier Mazuecos Quirós, Spain 004 Psychosexual correlates of unwanted sexual expe- riences in women consulting for female sexual dysfunction according to their timing across the life span Sarah Cipriani, Italy 005 The mechanisms of erectile dysfunction after administration of anticancer agents in rats Tomoya Kataoka, Japan 006 Prospective comparison between different regi- mens of skin disinfection prior to implantation of hydraulic penile prostheses Daniar Osmonov, Germany 007 Effect of change in exercise parameters and body composition on erectile quality and testosterone levels Ece Hattat, Turkey 008 Child sexual offending is associated with prenatal and epigenetic alterations of the androgen system Tillmann Krüger, Germany PS-05 PODIUM SESSION 08:00–09:30 Room E1-2 Hormones and medical treatment Chairs: Paolo Capogrosso, Italy Mikkel Fode, Denmark 001 The safety of sildenafil citrate in men with or without cardiovascular disease or risk factors Robert A. Kloner, USA 002 Collagenase clostridium histolyticum injections for Peyronie's Disease: Our experience, outcomes and predictive factors for 89 patients Giovanni Chiriaco, United Kingdom 003 The role of nutritional intervention in the treatment of male hypogonadism secondary to obesity Massimiliano Caprio, Italy 004 Discontinuation of dapoxetine treatment in patients with premature ejaculation: A 2-year prospective observational study Hyun-Jun Park, Republic of Korea 005 Low-intensity shockwave therapy for erectile dys- function: 6 months follow-up results of a rando- mized clinical trial assessing the impact of energy flux density and frequency of sessions Ioannis Mykoniatis, Greece 006 How uncommon penile curvatures influence clini- cal outcomes in patients with Peyronie‘s Disease receiving collagenase clostridium hystolyticum therapy? Andrea Cocci, Italy 007 Safety and efficacy of intra-cavernosal Botulinum toxin injection in the treatment of patients with severe erectile dysfunction Amr Abdel Raheem, United Kingdom 008 Recent trends in incidence of recorded erectile dysfunction, phosphodiesterase type 5 inhibitor prescriptions, hypogonadism and testosterone replacement therapy prescriptions in type 2 dia- betic patients in a primary care setting Patricia Schartau, United Kingdom 009 Both comorbidity burden and low testosterone can explain symptoms and sign of androgen deficiency in men consulting for sexual dysfunction Giovanni Corona, Italy 010 Effects of daily tadalafil 5mg administration on Post Micturition Dribbling (PMD) in men with lower urinary tract symptoms: A prospective, multicenter, double-blind, placebo-controlled, randomized clinical study Hyun-Cheol Jeong, Republic of Korea 011 The multimodal treatment for acute phase Peyro- nie's Disease Luigi Gallo, Italy